Glutamatergic modulation of cortical acetylcholine release in the rat: a combined in vivo microdialysis, retrograde tracing and immunohistochemical study.
The microdialysis technique with one or two probes was used to investigate the modulation of cortically projecting cholinergic neurons by glutamatergic input in the rat in vivo. Male albino Wistar rats (250-300 g) were used. Under chloral hydrate anaesthesia microdialysis membranes were positioned in the parietal cortex, nucleus basalis magnocellularis (NBM) or medial septum. Acetylcholine was assayed using high-performance liquid chromatography (HPLC) with electrochemical detection while GABA was detected using HPLC with fluorimetric detection after derivatization of the amino acid with o-phthalaldehyde. Septo-cortical neurons were retrogradely labelled with fluoro-gold. Double labelling with choline acetyltransferase (ChAT) immunoreactivity was performed to identify these neurons. Our main findings were that: (i) i.c.v. administration of the NMDA antagonist 3-((R)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP, 1-5 nmol) increased cortical acetylcholine outflow; (ii) local administration of CPP (100 microM) to the cortex had no effect on cortical acetylcholine outflow; (iii) local administration of CPP (100 microM) to the NBM decreased cortical acetylcholine outflow; (iv) local administration of CPP (100-200 microM) to the septum increased cortical GABA and acetylcholine outflow; (v) administration of muscimol to the septum prevented the effect of CPP on cortical acetylcholine outflow; (vi) retrograde tracing with fluoro-gold labelled cell bodies in the medial septum; (vii) septal fluoro-gold-positive neurons were not ChAT-immunoreactive. Our in vivo neurochemical results, in combination with retrograde tracing and immunohistochemistry, indicate that the cortically projecting cholinergic system is indirectly regulated by a glutamatergic input via a polysynaptic GABAergic circuitry located in the septum.
Giovannini
M G
MG
Department of Preclinical and Clinical Pharmacology, University of Florence, Italy.
Giovannelli
L
L
Bianchi
L
L
Kalfin
R
R
Pepeu
G
G
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005456:Fluorescent Dyes; D018755:GABA Agonists / Q000494:pharmacology; D018698:Glutamic Acid / Q000494:pharmacology*; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D008297:Male; D017551:Microdialysis; D009118:Muscimol / Q000494:pharmacology; D010296:Parietal Lobe / Q000187:drug effects* / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D013266:Stilbamidines
C049774:2-hydroxy-4,4'-diamidinostilbene, methanesulfonate salt; D018691:Excitatory Amino Acid Antagonists; D005456:Fluorescent Dyes; D018755:GABA Agonists; D010879:Piperazines; D016194:Receptors, N-Methyl-D-Aspartate; D013266:Stilbamidines; D009118:Muscimol; D018698:Glutamic Acid; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; D000109:Acetylcholine